+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Epidemiology of borderline ovarian tumors

Journal of the National Cancer Institute 78(1): 71-74

Epidemiology of borderline ovarian tumors

Ovarian tumors of low malignant potential, often termed "borderline tumors", have been defined as those that have some but not all of the morphologic features of malignancy (i.e., they are not invasive). With the use of data obtained by the western Washington population-based Cancer Surveillance System for 1975-83, the incidence of serous and mucinous borderline epithelial ovarian tumors was analyzed, as well as the survival of women who developed them. The incidence of borderline tumors increased with increasing age, although at a pace somewhat slower than that of malignant ovarian tumors. There was an upward trend in the incidence of borderline tumors starting in the late 1970's, a trend not present for malignant tumors. Only 12% of borderline tumors were not confined to the ovary, as opposed to 40% of malignant Grade I and 73% of other malignant ovarian neoplasms. At 5 years following diagnosis, the survival of women with borderline tumors was 93% that of the general female population. This percentage varied little by stage or histologic type. Given the reduced survival of women with these ovarian tumors and the lack of a sharp histological distinction between borderline and Grade I malignant lesions, it is recommended that borderline ovarian tumors be routinely ascertained by population-based cancer registries.

(PDF same-day service: $19.90)

Accession: 005375921

PMID: 3025504

DOI: 10.1093/jnci/78.1.71

Related references

Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960-2007. Acta Obstetricia et Gynecologica Scandinavica 95(4): 473-479, 2016

Borderline ovarian tumors in Finland: epidemiology and familial occurrence. American Journal of Epidemiology 144(6): 548-553, 1996

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). International Journal of Gynecological Cancer 24(9 Suppl 3): S5-S8, 2015

The borderland between benign and malignant surface epithelial ovarian tumors: Current controversy over the nature and nomenclature of borderline ovarian tumors. Cancer (Philadelphia) 76(10 SUPPL ): 2138-2142, 1995

Immunohistochemical study of the expression CD44 in serous, borderline, malign surface epithelial ovarian tumors and metastatic ovarian tumors. 2007

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT. Nuclear Medicine and Molecular Imaging 47(2): 81-88, 2014

Magnetic resonance imaging manifestations of ovarian mullerian mixed epithelial borderline tumors: imaging and histologic features in comparison with mullerian mucinous borderline tumors. Journal of Computer Assisted Tomography 39(2): 276-280, 2015

Ovarian tumors of low malignant potential (borderline ovarian tumors). Revista Medico-Chirurgicala A Societatii de Medici Si Naturalisti Din Iasi 115(2): 438-445, 2011

Ovarian stimulation for IVF treatment increases risk of borderline ovarian tumors later in life. 2011

Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertility and Sterility 104(1): 138-144, 2015